Browse > Article
http://dx.doi.org/10.5351/KJAS.2014.27.1.013

Maximum Tolerated Dose Estimation by Stopping Rule and SM3 Design in a Phase I Clinical Trial  

Kim, Byoungchan (Department of Biostatistics, The Catholic University of Korea)
Kim, Dongjae (Department of Biostatistics, The Catholic University of Korea)
Publication Information
The Korean Journal of Applied Statistics / v.27, no.1, 2014 , pp. 13-20 More about this Journal
Abstract
Phase I Clinical Trials estimate a Maximum Tolerated Dose(MTD). In this paper, an MTD estimation method applied stopping rule is proposed for Phase I Clinical Trials. The suggested MTD estimation method is compared to the Continual Reassessment Method(CRM) method using a Monte Carlo simulation study.
Keywords
Phase I clinical trial; maximum tolerated dose; stopping rule;
Citations & Related Records
Times Cited By KSCI : 2  (Citation Analysis)
연도 인용수 순위
1 Ahn, C. (1998). An evaluation of phase I cancer clinical trial designs, Statistics in Medicine, 17, 1537-1549.   DOI
2 Chevret, S. (1993). The continual reassessment method in cancer phase I clinical trials: A simulation study, Statistics in Medicine, 12, 1093-1108.   DOI   ScienceOn
3 Dixon, W. J. and Mode, A. M. (1948). A method for obtaining and analyzing sensitivity data, Journal of the American Statistical Association, 43, 109-126.   DOI   ScienceOn
4 Faries, D. (1994). Practical modi cations of the continual reassessment method for phase 1 cancer clinical trials, Journal of Biopharmaceutical Statistics, 4, 147-164.   DOI   ScienceOn
5 Goodman, S. N., Zhurak, M. L. and Piantadosi, S. (1995). Some practical improvements in the continual reassessment method for phase I studies, Statistics in Medicine, 14, 1149-1161.   DOI   ScienceOn
6 Kang, S. H. (2002). Investigation on the modi ed continual reassessment method in phase I clinical trial, Journal of Applied Statistics, 15, 323-336.
7 Kim, D. U. and Kil, S. K. (2009). Precision and safety comparison for SM, CRM and ATD in phase I clinical trials, Communications of the Korean Statistical Society, 16, 51-65.   과학기술학회마을   DOI   ScienceOn
8 Korn, E. L., Midthune, D., Chen, T. T., Rubinstein, L. V., Christian, M. C. and Simon, R. M. (1994). A comparison of two phase I trial designs, Statistics in Medicine, 13, 1799-1806.   DOI   ScienceOn
9 O'Quigley, J. and Chevret, S. (1991). Method for dose nding studies in cancer clinical trials: A review and results of a Monte Carlo study, Statistics in Medicine, 10, 1647-1664.   DOI   ScienceOn
10 Storer, B. E. (1989). Design and analysis of phase I clinical trials, Biometrics, 45, 925-937.   DOI   ScienceOn
11 Park, I. H. (1999). The estimation of maximal tolerated dose in sequential phase I clinical trials, Department of Biostatistics, The Catholic University of Korea, Biostatistics Master's Thesis.